Novel Drug Evitar™-“Sentinel Moment in Surgery”
 
Unprecedented Clinical Data in Adhesion Prevention Could Capture $3B Uncontested Market

 

Current literature suggests that addressing hypoxia and shifting anaerobic metabolism to aerobic metabolism could be a viable strategy to preventing post surgery adhesions. Evitar™ is a proprietary aqueous formulation of naturally occurring amino acids. In a double blind placebo controlled randomized study with three independent blinded medical reviewers, Evitar prevented adhesions in 83-89% of patients, a 5x improvement over placebo.


I believe the approach has potential to set a new standard of care in gynecology pelvic surgeries. For me it is important that it is not a barrier or medical devices which are not that effective. Read More  

Dr. James Greenberg Vice Chair Obs and Gyne, Brigham and Women's, Harvard Medical School


 


Learn More

View our R&D Pipeline

  • TTX-330 Orthopedics is a therapeutic and bioresorbable polymer combination that helps reduce fibrosis following joint surgeries.

  • TTX 334 is a novel therapeutic candidate being studied for the treatment of endometriosis.

  • TTX 334Ab Oncology is a novel monoclonal antibody candidate being studied for treating solid tumors with lead indication in chemo resistant ovarian cancer.

Our TEAM

  • “Evitar™ offers a potential therapeutic option for preventing adhesion formation based on sound scientific principles with the exciting triad of Efficacy, Safety and Ease of Use.”... Read More

    Dr. James Greenberg Vice Chair Obs and Gyne, Brigham and Women's, Harvard Medical School
  • Evitar™ provides a totally new pre-emptive concept, that actively intervenes in the molecular pathway of adhesion formation."... Read More

    Dr. Richard ten Broek MD PhD General Surgery Radboud UMC Nijmegen The Netherlands
View All Success Stories

MeEt Us

View our upcoming events

View All Events